Arcutis Biotherapeutics Inc
ARQT27.320USD
+1.250+4.79%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.29BMarket Cap
LossP/E TTM
More Details of Arcutis Biotherapeutics Inc Company
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Arcutis Biotherapeutics Inc Info
Ticker SymbolARQT
Company nameArcutis Biotherapeutics Inc
IPO dateJan 31, 2020
CEOWatanabe (Todd Franklin)
Number of employees342
Security typeOrdinary Share
Fiscal year-endJan 31
Address3027 Townsgate Road
CityWESTLAKE VILLAGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91361
Phone18054185006
Websitehttps://arcutis.com/
Ticker SymbolARQT
IPO dateJan 31, 2020
CEOWatanabe (Todd Franklin)
Company Executives of Arcutis Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+7609.00%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
553.10K
-61547.00%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
69.74K
-10000.00%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
64.93K
-88.00%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+16079.00%
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
--
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
24.38K
-1657.00%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
22.12K
-1232.00%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Dr. Patrick E. Burnett, M.D., Ph.D.
Dr. Patrick E. Burnett, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+7609.00%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
553.10K
-61547.00%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
69.74K
-10000.00%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
64.93K
-88.00%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+16079.00%
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Jan 22
Updated: Thu, Jan 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.78%
Suvretta Capital Management, LLC
8.55%
Frazier Life Sciences Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.19%
The Vanguard Group, Inc.
5.90%
Other
62.52%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.78%
Suvretta Capital Management, LLC
8.55%
Frazier Life Sciences Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.19%
The Vanguard Group, Inc.
5.90%
Other
62.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.71%
Investment Advisor/Hedge Fund
29.60%
Hedge Fund
26.83%
Private Equity
8.06%
Research Firm
5.40%
Individual Investor
1.75%
Venture Capital
1.74%
Pension Fund
0.36%
Bank and Trust
0.36%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
472
131.99M
121.03%
+141.06K
2025Q3
485
132.04M
126.61%
-572.34K
2025Q2
481
132.04M
123.15%
+2.05M
2025Q1
470
130.04M
130.14%
-24.35M
2024Q4
436
133.17M
134.30%
-68.58K
2024Q3
415
133.38M
130.85%
+1.94M
2024Q2
398
131.92M
132.27%
+3.16M
2024Q1
375
129.07M
110.42%
+2.15M
2023Q4
351
102.49M
100.39%
+16.40M
2023Q3
347
77.54M
150.28%
-4.60M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
10.75M
8.78%
--
--
Sep 30, 2025
Suvretta Capital Management, LLC
10.48M
8.55%
-1.06M
-9.17%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
9.87M
8.06%
-7.00
-0.00%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.58M
6.19%
-33.44K
-0.44%
Sep 30, 2025
The Vanguard Group, Inc.
7.12M
5.81%
+96.99K
+1.38%
Sep 30, 2025
Jennison Associates LLC
12.25M
10%
+1.14M
+10.30%
Sep 30, 2025
Polar Capital LLP
5.30M
4.33%
+292.28K
+5.84%
Sep 30, 2025
State Street Investment Management (US)
4.64M
3.79%
+114.38K
+2.53%
Sep 30, 2025
Gilder Gagnon Howe & Co. LLC
4.43M
3.62%
+273.35K
+6.58%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.95M
3.22%
+197.76K
+5.27%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Innovator IBD 50 Fund ETF
4.05%
Simplify Health Care ETF
3.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.79%
First Trust Small Cap Growth AlphaDEX Fund
1.17%
State Street SPDR S&P Biotech ETF
0.92%
Franklin Genomic Advancements ETF
0.69%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
ProShares Ultra Nasdaq Biotechnology
0.45%
First Trust Multi-Manager Small Cap Opportunities ETF
0.39%
First Trust Active Factor Small Cap ETF
0.36%
View more
Innovator IBD 50 Fund ETF
Proportion4.05%
Simplify Health Care ETF
Proportion3.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.79%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.17%
State Street SPDR S&P Biotech ETF
Proportion0.92%
Franklin Genomic Advancements ETF
Proportion0.69%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.56%
ProShares Ultra Nasdaq Biotechnology
Proportion0.45%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.39%
First Trust Active Factor Small Cap ETF
Proportion0.36%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
